Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway are expected to be a novel therapy for combating future increases in numbers of malignant pleural mesothelioma (MPM) patients. However, the PD-L1 expression, which is a predictor of the response to ICIs, is unclear in MPM. We studi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Watanabe, Takuya, Okuda, Katsuhiro, Murase, Takayuki, Moriyama, Satoru, Haneda, Hiroshi, Kawano, Osamu, Yokota, Keisuke, Sakane, Tadashi, Oda, Risa, Inagaki, Hiroshi, Nakanishi, Ryoichi
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5945532/
https://ncbi.nlm.nih.gov/pubmed/29755688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25100
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados